Initiating sacubitril/valsartan (LCZ696) in heart failure: results of TITRATION, a double‐blind, randomized comparison of two uptitration regimens

AIMS: To assess the tolerability of initiating/uptitrating sacubitril/valsartan (LCZ696) from 50 to 200 mg twice daily (target dose) over 3 and 6 weeks in heart failure (HF) patients (ejection fraction ≤35%). METHODS AND RESULTS: A 5‐day open‐label run‐in (sacubitril/valsartan 50 mg twice daily) pre...

Descripción completa

Detalles Bibliográficos
Autores principales: Senni, Michele, McMurray, John J.V., Wachter, Rolf, McIntyre, Hugh F., Reyes, Antonio, Majercak, Ivan, Andreka, Peter, Shehova‐Yankova, Nina, Anand, Inder, Yilmaz, Mehmet B., Gogia, Harinder, Martinez‐Selles, Manuel, Fischer, Steffen, Zilahi, Zsolt, Cosmi, Franco, Gelev, Valeri, Galve, Enrique, Gómez‐Doblas, Juanjo J., Nociar, Jan, Radomska, Maria, Sokolova, Beata, Volterrani, Maurizio, Sarkar, Arnab, Reimund, Bernard, Chen, Fabian, Charney, Alan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd 2016
Materias:
Medical Treatment
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5084812/
https://www.ncbi.nlm.nih.gov/pubmed/27170530
http://dx.doi.org/10.1002/ejhf.548

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5084812/
https://www.ncbi.nlm.nih.gov/pubmed/27170530
http://dx.doi.org/10.1002/ejhf.548

Ejemplares similares